The combination of brentuximab vedotin and nivolumab demonstrated activity in patients with previously untreated Hodgkin lymphoma who had comorbidities in a phase 2 clinical trial, despite the trial not meeting its prespecified criteria for activity.
In an interview with Targeted Oncology, Nirav N. Shah, MD, discussed the findings from the phase 1 study of a CAR T-cell therapy dual targeting CD19 and CD20 as treatment of patients with B-cell lymphomas.
Promising antitumor activity, as well as an acceptable safety profile, continues to be demonstrated with odronextamab, a novel CD20xCD3 bispecific antibody, as treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
In patients with relapsed or refractory lymphoma, treatment with the investigational CD47-blocker TTI-622 appeared well tolerated and demonstrated preliminary activity, according to results from a phase 1a clinical trial presented in a poster during the 2020 American Society of Hematology Virtual Annual Meeting.
Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
In a phase 1 study of patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, the anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 demonstrated activity, durable responses, safety, and tolerability.